Models of progression in AD
Predicting disability and costs
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Three articles in this issue of Neurology use AD patient databases to develop models that predict patient movement among the stages of AD.1-3⇓⇓ These articles illustrate how models can be built based on many short observation intervals (months) to predict the behavior of a disease such as AD which takes years to run its course. Costs and progression are associated with either the group or the individuals in each stage to determine how much would be saved if a treatment alters the dynamics of disease progression. The concept of model-building is not new to the AD literature,4-6⇓⇓ in which earlier models explored cognitive changes using different types of regression analyses instead of survival approaches. However, caution must be exercised when interpreting results from any model that is built from a particular dataset because the characteristics of the underlying data can limit their clinical application.
Neumann et al.1 used the Consortium to Establish a Registry in AD (CERAD)7 database to estimate the probability of moving among the mild, moderate, and severe stages of AD with transition to death possible from any of these stages. They modeled the holding time of an individual in each AD stage using the Cox proportional hazard statistical model that adjusts for patient heterogeneity defined by patient …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Deborah Friedman and Dr. Stacy Smith
► Watch
Related Articles
Alert Me
Recommended articles
-
Articles
Assessment of health economics in Alzheimer’s disease (AHEAD)Galantamine treatment in CanadaD. Getsios, J. J. Caro, G. Caro et al.Neurology, September 25, 2001 -
Articles
Assessment of health economics in Alzheimer’s disease (AHEAD) based on need for full-time careJ. J. Caro, D. Getsios, K. Migliaccio–Walle et al.Neurology, September 25, 2001 -
Article
Clinicopathologic differences among patients with behavioral variant frontotemporal dementiaMario F. Mendez, Simantini J. Karve, Kanida Tassniyom et al.Neurology, January 16, 2013 -
Article
Randomized controlled trials in mild cognitive impairmentSources of variabilityRonald C. Petersen, Ronald G. Thomas, Paul S. Aisen et al.Neurology, April 05, 2017